


National Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for Medicare, Medicaid, Medicaid managed care, and commercial managed care organizations across the nation from January 2017 through December 2017.

Key National Findings



Initial Rejection Rate

46%


- Commercial: **60%**
- Medicare: **36%**



Final Rejection Rate

26%

- Commercial: **46%**
- Medicare: **15%**



Final Rejections

78,664



Total Claims

292,143



Of national health plans that received at least 2,000 claims for PCSK9 inhibitors, the following had **the highest rates of rejection**:

- Federal Employee Benefit Plan **83%**
- Anthem **45%**
- Tricare Military Health SVC SYS **49%**
- Express Scripts **38%**

The following tables detail claims data for managed care organizations across the country that received at least 2,000 claims for PCSK9 inhibitors.

Commercial Managed Care Organization	Rejection %	Total Claims	Rejections
Federal Employee Benefit Plan	83%	3,438	2,840
Anthem	76%	2,452	1,853
CVS Health	66%	5,641	3,737
United Health Group	62%	8,393	5,212
Express Scripts	53%	8,931	4,735
Tricare Military Health SVC SYS	49%	4,120	2,024

Data source: National data supplier; Commercial plans; January-December 2017

Medicare Managed Care Organization	Rejection %	Total Claims	Rejections
United Health Group	21%	34,608	7,433
Anthem	21%	3,029	621
Wellcare Management Group	20%	5,214	1,054
CVS Health	17%	22,400	3,751
UAW Retiree Medical Benefits Trust	16%	2,069	340
Cigna Healthcare	16%	5,391	843

Data source: National data supplier; Medicare, January-December 2017



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

